Drug Topics

DECEMBER 9, 2022

A group of pharmacists rose to the occasion to help a man having a medical emergency aboard a recent United flight bound for Newark, New Jersey.

275

275

PhRMA

DECEMBER 9, 2022

With a divided Congress, bipartisan action will be necessary to move the needle on health care policy. On December 7, 2022, PhRMA sponsored the Axios event, “ The Post-Midterm Health Care Agenda ,” where I participated in a View from the Top segment with Nicholas Johnston, publisher of Axios. We discussed PhRMA’s focus on passing the PASTEUR Act in the last few weeks of 2022, and laid out PhRMA’s priorities heading into 2023 that will support and protect patients.

Insurance 224

Insurance 224

Pharmacy Times

DECEMBER 6, 2022

Increasing workplace diversity, addressing health disparities, and overcoming disruptions from COVID-19 are considered top goals among pharmacy stakeholders.

156

156

STAT

DECEMBER 8, 2022

Doctors across the country, especially those in primary care, have been up in arms about Medicare’s proposed cuts in reimbursement that are scheduled to go into effect on January 1. They are concerned — rightfully so — that these cuts will be ruinous to their practices and compromise the care they can provide to their patients. As an emergency physician, I worry about the cuts for a different reason: emergency departments might soon be filled with more and more people who ca

143

143

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

Drug Topics

DECEMBER 5, 2022

Ann Anaya and Dean Kathleen Kennedy discuss the importance of diversity in pharmacy and why it matters that patients are treated by someone who looks them. Plus, Good Neighbor Pharmacy launches a scholarship program to help address these needs.

211

211

pharmaphorum

DECEMBER 7, 2022

Elon Musk’s brain computer interface (BCI) company Neuralink is being investigated by law enforcement authorities in the US amid allegations of animal welfare violations in its testing facilities. Neuralink’s BCI is intended to treat conditions like blindness and spinal cord injury, as well as provide a way to interact with digital devices using the brain and, according to Musk, is on the brink of moving into the human testing stage.

Medical Records 122

Medical Records Documentation 122

STAT

DECEMBER 6, 2022

Two vastly different experiences — serving as a “guest coach” on the sidelines for a Division I football team and volunteering in a busy emergency department — showed me just how unequal and damaging the lack of care provided for women who are victims of domestic violence can be. In the first decade of the 2000s, one of the benefits of being a professor at Wake Forest University was the opportunity I received nearly every year to serve as a guest coach.

143

143

Drug Topics

DECEMBER 9, 2022

Winner of SingleCare's Best of the Best: Best Pharmacy Technician, Santon joined Drug Topics® to discuss what pharmacy technicians can do for patients and why it's so important to her for every patient to afford their medication.

CPhT 187

CPhT 187

Pharmaceutical Technology

DECEMBER 8, 2022

Kite Pharma and Daiichi Sankyo have updated a partnership agreement signed in 2017 for the former’s CAR T-cell therapy, Yescarta (axicabtagene ciloleucel). Under the prior deal, Daiichi Sankyo acquired exclusive rights for the development, manufacturing and commercialisation of Yescarta in Japan. Subsequently, in the same year, Gilead Sciences acquired Kite.

Communication 122

Communication Immunization Hospitals 122

Pharmacy Times

DECEMBER 9, 2022

The decision is updated from a 2017 recommendation to screen people for obstructive sleep apnea, which can lead to daytime sleepiness and other adverse outcomes.

139

139

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

STAT

DECEMBER 9, 2022

There’s been significant investment in companies creating artificial intelligence (AI) applications for health and health care over the last decade. But while there have been successes, notably in the area of medical imaging, the industry is known more for not yet living up to its potential — think IBM Watson. The slow pace of AI adoption in health care stems from the fact that health AI sits on the border between two large industries, health care and tech.

140

140

Drug Topics

DECEMBER 5, 2022

Short-term manufacturing problems are happening as the demand for Adderall and other stimulant medications for ADHD have increased. Data from Arrive Health show a marked increase in ADHD medication prescriptions for people in their 30s.

187

187

pharmaphorum

DECEMBER 5, 2022

A digital health assistant that can help people at risk of becoming dependent on alcohol has been launched in Belize, its first country, by the World Health Organisation (WHO) and Pan-American Health Organisation (PAHO). The artificial intelligence-powered assistant – called Pahola and available as a free online chat-based site – is designed to provide information and guidance to help people reduce their alcohol consumption, helping to prevent more than 200 health conditions linked to excessive

122

122

Pharmacy Times

DECEMBER 9, 2022

Palivizumab is a humanized monoclonal antibody approved by the FDA to prevent serious lower respiratory tract infection caused by respiratory syncytial virus in infants and young children.

FDA 130

FDA 130

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management Software

STAT

DECEMBER 7, 2022

For many patients, one of the most antagonizing parts of a hospital visit is paying for parking. Those parking fees aren’t just an annoyance for the sick and injured, according to a new paper in the Journal of Medical Imaging and Radiation Sciences. The charges are actually eating into their financial well-being, particularly for people who have cancer and have to make frequent visits to the hospital for treatments like radiation and chemotherapy.

Hospitals 135

Hospitals Chemotherapy 135

Drug Topics

DECEMBER 7, 2022

Recent research looks at how the pandemic impacted the uptake of the human papillomavirus vaccine, which has traditionally lagged behind other pediatric vaccine rates.

Vaccines 186

Vaccines 186

The FDA Law Blog

DECEMBER 7, 2022

By Mark A. Tobolowsky & James E. Valentine — On November 22, 2022, FDA approved CSL Behring’s BLA for Hemgenix (etranacogene dezaparvovec), an AAV-based gene therapy for the treatment of adults with Hemophilia B who currently use Factor IX prophylaxis therapy, have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

FDA 119

FDA Packaging 119

Pharmacy Times

DECEMBER 5, 2022

Jacinda Abdul-Mutakabbir, assistant professor of Pharmacy Practice at Loma Linda University, discusses how pharmacists can improve vaccination rates and learn from the pandemic.

Vaccines 130

Vaccines 130

PharmExec

DECEMBER 8, 2022

Our annual report spotlighting notable investments in new drug development captures a mix of gradual gains and giant leaps—both equally as promising—in five expanding and diverse therapeutic areas: spinal muscular atrophy, hemophilia A, intranasal and inhaled vaccines, gene-targeted therapy, and RNA therapeutics.

Vaccines 119

Vaccines 119

Drug Topics

DECEMBER 7, 2022

Not every pharmacist may feel comfortable administering vaccines to children, but education could help.

Vaccines 220

Vaccines 220

STAT

DECEMBER 7, 2022

Touted by celebrities, raved about by TikTok users and advertised by med spas, a new class of drugs for treating diabetes and obesity has exploded in popularity for its weight-loss effects, leading to rippling shortages across several of the medications. Amid the surge in demand, Eli Lilly and pharmacies have started to tighten access to the latest of this type of drug, tirzepatide, focusing on giving it to people with type 2 diabetes, the only population it’s authorized for so far.

119

119

Pharmacy Times

DECEMBER 8, 2022

Study finds men are more likely to be prescribed statins and women are more likely to be advised to make lifestyle changes to lessen the risk of cardiovascular disease.

131

131

pharmaphorum

DECEMBER 4, 2022

Clinical trials of a wireless brain chip developed by Elon Muck’s Neuralink company will be tested in human volunteers within the next six months – and Musk himself says he intends to have one implanted for a future demo event. Neuralink has been promising that the technology will be ready for clinical trials soon for some time – first saying they were around the corner back in 2019 – so the latest announcement by Musk at an update last week may be met with some scepticism.

FDA 118

FDA 118

Drug Topics

DECEMBER 6, 2022

Faced with access problems, women could be positively impacted by pharmacists having prescribing powers in New York state.

201

201

STAT

DECEMBER 7, 2022

Americans may be returning to their pre-pandemic habits , but most have not returned to their primary care doctors. Primary care visits are down 10.3% on average across U.S. cities relative to pre-pandemic levels. That, combined with more people with chronic diseases like diabetes, obesity, and cancer, and accelerating health care costs as inflation soars, signal a troubled future for the health of Americans and the U.S.

119

119

Pharmacy Times

DECEMBER 9, 2022

At 3 and 6 months, rivaroxaban was found to be as effective and safe as apixaban in the composite outcome of recurrent venous thromboembolism or bleeding-related hospitalization.

Hospitals 121

Hospitals 121

pharmaphorum

DECEMBER 8, 2022

Ramesh “Sunny” Balwani, the former business partner of Theranos founder Elizabeth Holmes, has been sentenced to nearly 13 years in prison after being convicted of wire fraud. His sentencing comes after ex-Theranos chief executive Holmes was given more than 11 years in prison last month after also being found guilty of defrauding investors in Theranos, which said it had developed technology that could diagnose a host of diseases with just a few drops of blood taken with a finger prick, rather tha

Documentation 111

Documentation Communication 111

Drug Topics

DECEMBER 7, 2022

Knowledge gaps can make OTC medication recommendations for this population a challenge.

232

232

STAT

DECEMBER 6, 2022

In a significant victory, Apple has successfully challenged patents at the center of a high-profile dispute with medical device company AliveCor. The U.S. Patent and Trademark Office’s Patent Trial and Appeal Board, or PTAB, on Tuesday ruled that three AliveCor patents covering heart monitoring technologies for wearable devices were unpatentable.

111

111

Pharmacy Times

DECEMBER 8, 2022

Based on the ALIFE 2 trial results, the investigators do not advise the routine use of low-molecular-weight heparin in women with recurrent pregnancy loss and confirmed inherited thrombophilia.

122

122

Pharmafile

DECEMBER 6, 2022

San Francisco, US-based Nkarta have been assessing the power of natural killer (NK) cells in oncology treatments. The treatment is as-yet unproven but appears hopefully at this early stage. Nkarta has just reported results from an early-stage trial of its CAR-NK therapies, which looks likely to generate enthusiasm to this area of research. read more.

106

106

Drug Topics

DECEMBER 6, 2022

Diabetes self-management education and diabetes prevention programs can improve patient outcomes including mental health and HbA1C.

187

187

STAT

DECEMBER 7, 2022

An investigative medicine from Prometheus Biosciences met its goals in a pair of Phase 2 studies enrolling patients with inflammatory bowel disease, setting the stage for pivotal trials and nearly doubling the company’s stock price. In an ulcerative colitis study enrolling about 130 volunteers, Prometheus’ drug helped nearly 27% of patients reach clinical remission, defined as an absence of serious symptoms, compared to 1.5% for the placebo group, the company said.

Labelling 111

Labelling 111

Pharmacy Times

DECEMBER 6, 2022

Tom Greenlee, retail pharmacy manager at the University of Missouri Health Care, and Kayla Hodges, 340B Analyst in Pharmacy Business at the University of Missouri Health Care, discusses how a successful career ladder can help retain pharmacy technicians.

119

119